Start Free Trial
Pricing
Log In
Log In
Upgrade browser for full Crunchbase experience. You're accessing Crunchbase in a browser that is no longer supported.
Learn More
BIOVALLEY Logo
BIOVALLEY Growth Score
28
CB Rank
235296
Heat Score
65
BIOVALLEY is a pharmaceutical company that engages in drug development businesses.
Founded
obfuscation
PublicPost-IPO Equity Kunming, Yunnan, China251-500 www.biovalley.cn/
Biotechnology
Health Care
Medical
Pharmaceutical
Overview

BIOVALLEY
Total Funding
obfuscation
Growth Score
28
Heat Score
65

Total Funding
obfuscation
obfuscation
Post-IPO Equity raised
obfuscation
Growth Score28
-3 pts
in past quarter
Heat Score 65
-11 pts
in past quarter

Company Performance Metrics

Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Learn More >
See more interactive data and historical milestones on desktop for the best experience

About BIOVALLEY

CB Rank
235296
BIOVALLEY is a pharmaceutical company that engages in drug development businesses.
Founded
obfuscation
PublicPost-IPO Equity Kunming, Yunnan, China251-500 www.biovalley.cn/
Biotechnology
Health Care
Medical
Pharmaceutical

Funding Rounds

Post-IPO Equity
OBF
in
obfuscation

Details

Legal Name Yunnan Biovalley Pharmaceutical Co., Ltd.
Also Known As 云南生物谷药业股份有限公司, 生物谷, Shengwugu
Operating Status Active
Stock Symbol  NEEQ:833266
Company Type For Profit
About the Company
Biovalley manufactures and sells the breviscapine series of drugs. They provide injections, capsules, tablets, dripping pills, erigeron capsules, and soft capsules. They provide solutions for ischemic cardiovascular and cerebrovascular diseases, stroke sequelae, and coronary heart disease treatment.
Phone Number 0871-65016111
Predictions & Insights

Products & Services

Dengzhan Su Mai Capsule (灯盏生脉胶囊)
A capsule formulation used for improving blood circulation and treating cardiovascular conditions.
Dengzhan Xixin Injection (灯盏细辛注射液)
An injectable formulation used for therapeutic purposes related to blood circulation and cardiovascular health.

Unlock More with Crunchbase Pro
  • Full access to financial & funding data on unlimited profiles
  • Export up to 2k results/month for analysis
  • Track market signals on competitors, products, and R&D
  • Preview private company insights and predictions
Financials

Company Funding

Total Funding Amount 
obfuscation
Number of Funding Rounds 1
Unlock company funding data, including rounds, dates, amounts, and investors.
Announced Date  
Transaction Name  
Number of Investors  
Money Raised  
Lead Investors  
Funding Type  
obfuscation
Post-IPO Equity - BIOVALLEY Logo
Post-IPO Equity - BIOVALLEY
1
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - BIOVALLEY Logo
Post-IPO Equity - BIOVALLEY
1
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - BIOVALLEY Logo
Post-IPO Equity - BIOVALLEY
1
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - BIOVALLEY Logo
Post-IPO Equity - BIOVALLEY
1
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - BIOVALLEY Logo
Post-IPO Equity - BIOVALLEY
1
obfuscation
— Post-IPO Equity

Funding Rounds

Total Funding Amount 
obfuscation
Number of Funding Rounds 1
Unlock company funding data, including rounds, dates, amounts, and investors.
Announced Date  
Transaction Name  
Number of Investors  
Money Raised  
Lead Investors  
Funding Type  
obfuscation
Post-IPO Equity - BIOVALLEY Logo
Post-IPO Equity - BIOVALLEY
1
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - BIOVALLEY Logo
Post-IPO Equity - BIOVALLEY
1
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - BIOVALLEY Logo
Post-IPO Equity - BIOVALLEY
1
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - BIOVALLEY Logo
Post-IPO Equity - BIOVALLEY
1
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - BIOVALLEY Logo
Post-IPO Equity - BIOVALLEY
1
obfuscation
— Post-IPO Equity

Investors

Market Intelligence
People
View Profiles & Contacts
Headcount 251-500
News

News and Press

News•Feb 1, 2022
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
Access a complete feed of recent news and press, from product launches to leadership changes.
Technology
View Tech Report

Monthly Web Visits

70

Active Website Tech Count

15BIOVALLEY is actively using 15 technologies for its website, according to BuiltWith. These include Viewport Meta, IPhone / Mobile Compatible, and  Euro.

Total IP

6The intellectual property of BIOVALLEY includes 6 registered patents primarily in the 'Medical Or Veterinary Science; Hygiene' category, according to IPqwery.
Sub-Organizations
Frequently Asked Questions

Where is BIOVALLEY's headquarters? BIOVALLEY is located in Kunming, Yunnan, China.Who invested in BIOVALLEY? BIOVALLEY is funded by ShenZhen GTJA Investment Group.When was the last funding round for BIOVALLEY? BIOVALLEY closed its last funding round on
obfuscation
from a Post-IPO Equity round.Who are BIOVALLEY's competitors? Alternatives and possible competitors to BIOVALLEY may include Jiuzhitang, Youcare Pharmaceutical Group, and  Jilin Huakang Pharmaceutical.How much funding has BIOVALLEY raised to date? BIOVALLEY has raised
obfuscation
.
Who We Are
What We Do
Helpful Links
AI Content may contain mistakes and is not legal, financial or investment advice. Learn more.
Terms of Service | Privacy Policy | Sitemap | © 2026 Crunchbase Inc. All Rights Reserved.
(ccb7a32 1)
|